Cases
AmerisourceBergen Corporation (ABC)
Securities Class Action
Overview
Overview
- Date:
- 10/26/2018
- Company Name:
- AmerisourceBergen Corporation
- Stock Symbol:
- ABC
- Status:
- Closed/Complete
NEW YORK, October 26, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of AmerisourceBergen Corporation (NYSE: ABC).
In September 2017, the company’s AmerisourceBergen Specialty Group unit pleaded guilty to a misdemeanor related to the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors, and paid $260 million in criminal fines and forfeitures. The company also entered a five-year corporate integrity agreement to ensure compliance with federal health care rules.
On October 1, 2018, the U.S. Department of Justice announced that the company will pay $625 million to resolve civil fraud charges over related conduct, bringing AmerisourceBergen’s total payments to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration.
If you are a long term stockholder of AmerisourceBergen, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
In September 2017, the company’s AmerisourceBergen Specialty Group unit pleaded guilty to a misdemeanor related to the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors, and paid $260 million in criminal fines and forfeitures. The company also entered a five-year corporate integrity agreement to ensure compliance with federal health care rules.
On October 1, 2018, the U.S. Department of Justice announced that the company will pay $625 million to resolve civil fraud charges over related conduct, bringing AmerisourceBergen’s total payments to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration.
If you are a long term stockholder of AmerisourceBergen, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.